Snyder Capital Management L P Raises Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Snyder Capital Management L P lifted its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 15.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 177,927 shares of the medical research company's stock after acquiring an additional 24,086 shares during the quarter. Snyder Capital Management L P owned 0.35% of Charles River Laboratories International worth $32,845,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in CRL. Two Sigma Securities LLC grew its position in shares of Charles River Laboratories International by 4.3% during the fourth quarter. Two Sigma Securities LLC now owns 1,981 shares of the medical research company's stock valued at $366,000 after purchasing an additional 81 shares in the last quarter. Kovitz Investment Group Partners LLC bought a new position in shares of Charles River Laboratories International in the 4th quarter valued at about $217,000. Dauntless Investment Group LLC bought a new position in shares of Charles River Laboratories International in the 4th quarter valued at about $422,000. D1 Capital Partners L.P. bought a new position in shares of Charles River Laboratories International in the 4th quarter valued at about $172,752,000. Finally, Kerrisdale Advisers LLC lifted its holdings in shares of Charles River Laboratories International by 33.2% in the 4th quarter. Kerrisdale Advisers LLC now owns 8,665 shares of the medical research company's stock valued at $1,600,000 after acquiring an additional 2,160 shares during the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories International Trading Down 0.0 %

Charles River Laboratories International stock traded down $0.02 during midday trading on Wednesday, hitting $117.27. 254,384 shares of the stock were exchanged, compared to its average volume of 925,389. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $254.15. The stock has a market capitalization of $5.76 billion, a price-to-earnings ratio of 781.80, a PEG ratio of 4.54 and a beta of 1.45. The stock's 50-day simple moving average is $144.83 and its 200 day simple moving average is $170.07. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.16. The firm had revenue of $1 billion during the quarter, compared to analysts' expectations of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. Charles River Laboratories International's revenue was down 1.1% compared to the same quarter last year. During the same period last year, the business earned $2.46 earnings per share. On average, equities analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insiders Place Their Bets

In other Charles River Laboratories International news, CEO James C. Foster acquired 6,075 shares of the stock in a transaction dated Thursday, February 20th. The stock was acquired at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the purchase, the chief executive officer now owns 183,639 shares in the company, valued at $30,302,271.39. This trade represents a 3.42 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the firm's stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the transaction, the executive vice president now directly owns 20,013 shares of the company's stock, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their position. The disclosure for this sale can be found here. 1.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several analysts have issued reports on CRL shares. Citigroup raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and raised their price objective for the stock from $155.00 to $175.00 in a research note on Tuesday, March 4th. Mizuho decreased their price target on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a research note on Wednesday, April 9th. The Goldman Sachs Group cut Charles River Laboratories International from a "buy" rating to a "neutral" rating and decreased their price target for the company from $190.00 to $170.00 in a research note on Friday, March 21st. Barclays reduced their price objective on Charles River Laboratories International from $160.00 to $145.00 and set an "equal weight" rating for the company in a research note on Thursday, April 10th. Finally, JPMorgan Chase & Co. reduced their price objective on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a research note on Thursday, February 20th. One investment analyst has rated the stock with a sell rating and sixteen have given a hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $182.00.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).